The model incorporates 2 newly identified independent mortality risk factors in patients requiring second-line targeted therapy.
Active surveillance equal to partial nephrectomy for renal function preservation.
In separate studies, nivolumab prolonged overall survival and cabozantinib improved progression-free survival compared with everolimus.
Trend mirrors move to targeted therapy era.
Higher risk for clear cell, papillary renal cell carcinoma, but not chromophobe histology.
Increased risk for treatment-related subsequent neoplasms even beyond age 40 years.
Quality of life can be improved without adversely affecting outcomes.
New data suggest a prognosis role for the neutrophil to lymphocyte ratio.
Completely intracorporeal robotic level III inferior vena cava tumor thrombectomy viable.
Older adults react differently to treatment, oncology group notes.
Almost 1 in 3 not told cancer treatment might affect future fertility.
No improvement in quality of life, even for patients with good baseline performance status.
Radical and partial nephrectomy for renal cell carcinoma are associated with a similar risk of end-stage renal disease (ESRD), according to research.
High dietary intake of this antioxidant decreased the risk of renal cell carcinoma, according to a recent meta-analysis.
In a study, the treatment was associated with a 53% decreased risk of death from kidney cancer compared with expectant management.
Bevacizumab, sorafenib, and temsirolimus combinations did not improve progression-free survival in renal cell carcinoma (RCC).
80% of lung cancer deaths linked to smoking, researchers say.
Asymptomatic presentation, T3 low-grade tumors, and negative lymph nodes are associated with better progression-free and overall survival.
Study findings contradict those of previous investigators.
Two-thirds of patients feel that tumor profiling could improve their treatment; many will pay out of pocket.
Data suggest that a 7% or 8% cut-off rather than the conventional 30% is a better predictor in patients treated for mRCC.
RCC tumor shrinkage significantly and independently predicted overall survival.
Neoadjuvant sunitinib was linked to primary tumor and thrombus shrinkage, reduced blood loss during surgery, as well as improved cancer-specific survival.
Pathological stage was the only independent factor linked to kidney cancer progression.
The approach was defined as surgical resection with a wide margin or radiotherapy with a biologically effective dose of 140 Gy or greater.
In a study, patients who had the procedure had a better 5-year overall survival rate than those who did not (68% vs. 27%).
New finding may inform treatment decisions.
It is important to assess factors that may put patients at higher risk of metastatic disease, according to researchers.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)